MedPath

COMPARISON OF INJECTION CARBETOCIN WITH INJECTION OXYTOCIN IN VAGINAL DELIVERY FOR PREVENTION OF BLOOD LOSS

Not Applicable
Conditions
Health Condition 1: O721- Other immediate postpartum hemorrhage
Registration Number
CTRI/2024/03/063466
Lead Sponsor
DATTA MEGHE INSTITUTE OF HIGHER EDUCATION AND RESEARCH
Brief Summary

Not available

Detailed Description

Not available

Recruitment & Eligibility

Status
ot Yet Recruiting
Sex
Not specified
Target Recruitment
0
Inclusion Criteria

REPRODUCTIVE AGE GROUP AND ELIGIBLE FOR STUDY

SINGLETON PREGNANCY

TERM GESTATION

Exclusion Criteria

WOMEN WITH KNOWN COAGULOPATHY

STUDY DRUG HYPERSENSITIVITY

OLIGOHYDRAMNIOS OR POLYHYDRAMNIOS

CARDIAC DISEASES (INCLUDING DYSRHYTHMIA)

HYPERTENSION

LIVER,RENAL OR ENDOCRINE DISEASES (EXCEPT GESTATIONAL DIABETES)

UTERINE FIBROIDS OR SUSPICION OF PLACENTAL PATHOLOGY (ACRETA, PREVIA OR ABRUPTIO)

Study & Design

Study Type
Observational
Study Design
Not specified
Primary Outcome Measures
NameTimeMethod
INTRA-PARTUM BLOOD LOSS <br/ ><br>UTERINE TONETimepoint: 24 HOURS
Secondary Outcome Measures
NameTimeMethod
DIFFERENCE IN HEMOGLOBIN TAKEN BEFORE THE VAGINAL DELIVERY AND 48 HOURS AFTER VAGINAL DELIVERY <br/ ><br>NEED FOR ADDITIONAL UTEROTONICS <br/ ><br>EVALUATION OF NAUSEA AND VOMITINGTimepoint: 48 HOURS
© Copyright 2025. All Rights Reserved by MedPath